Dr. Reddy’s gets U.S. FDA tentative approval for HIV drug lenacapavir
Summary
- The U.S. Food and Drug Administration (FDA) granted a tentative approval to lenacapavir, an investigational HIV-1 capsid inhibitor developed by Dr. Reddy’s Laboratories.
- Lenacapavir is intended for the treatment of HIV-1 infection in adults with multi‑drug‑resistant virus or in patients who have limited treatment options.
- The tentative approval enables the drug to be marketed in the U.S. under the FDA’s “tentative approval” pathway, primarily to facilitate purchase by U.S. government procurement programs such as PEPFAR.
- Dr. Reddy’s aims to launch lenacapavir in the U.S. market later this year, complementing its existing portfolio of generic and specialty medicines.
Key Facts
- · Drug name: lenacapavir (also known as GS‑6207).
- · Approval type: U.S. FDA tentative approval.
- · Therapeutic class: HIV‑1 capsid inhibitor.
- · Target group: adults with multi‑drug‑resistant HIV.
- · Potential market: U.S. government HIV programs (e.g., PEPFAR).
- · Company: Dr. Reddy’s Laboratories Ltd., Indian pharma firm.
Why it matters
The approval marks the first FDA tentative nod for an Indian‑origin HIV capsid inhibitor, showcasing India’s growing R&D capabilities in advanced therapeutics and potentially expanding treatment options for drug‑resistant HIV worldwide.
#pharma#FDA#HIV#lenacapavir#Dr Reddy's#healthcare